H.C. Wainwright analyst Swayampakula Ramakanth downgraded Alaunos Therapeutics to Neutral from Buy without a price target after the company announced its decision to wind down the Phase 1/2 study of its T cell receptor and focus on seeking partnership for its human neoantigen T-cell receptor platform. The firm currently does not account for any potential revenues from the hunTR platform. A
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TCRT:
- Laidlaw downgrades Alaunos to Hold on ‘uncertain future’
- Alaunos Therapeutics downgraded to Hold from Buy at Laidlaw
- Alaunos Therapeutics reports Q2 EPS (4c), consensus (4c)
- ZIOPHARM Oncology trading resumes
- Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
